RxDoctor Payments Data

Francisco Cervoni, MD

Internal Medicine · Sarasota, FLNPI 1790774792

Payments from drug & device makers

$1,133in general payments, 2019–2025

Across 15 payments — averaging $75.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$243
  • GSK$240
  • Centinel Spine, LLC$155
  • Inspire Medical Systems, Inc.$128
  • Lilly USA, LLC$117
  • Astellas Pharma US Inc$75
  • plus $175 from 4 others

What the payments were for

  • Food & beverage$1,05893%
  • Education$757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,133 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$70,507
Medicare patients
366
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$38,438
EliquisApixaban37$34,342
JanuviaSitagliptin Phosphate19$21,879
XareltoRivaroxaban21$20,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$18,273
MyrbetriqMirabegron14$18,013
Repatha SyringeEvolocumab12$13,338
TradjentaLinagliptin11$10,361
SymbicortBudesonide/Formoterol Fumarate18$7,330
Losartan Potassium272$2,869
Rosuvastatin Calcium204$2,772
Atorvastatin Calcium323$2,535
SynthroidLevothyroxine Sodium30$2,268
Levothyroxine Sodium225$2,256
Potassium Chloride63$1,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$74$21,87919 claims
GSKTrelegy Ellipta$240$18,27318 claims
Astellas Pharma US IncMyrbetriq$75$18,01314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →